date:Apr 24, 2014
dition, and despite all the re-examinations and reviews filed by its competitors, the USPTO continues to grant patents to Neptune, the company notes.
Neptune said that it remains confident in its legal strategy and will continue to actively defend its intellectual property. It will continue to pursue Enzymotec before the ITC, with the ITC hearing (trial) scheduled to commence on April 28, 2014. A decision will be rendered by the Administrative Law Judge (ALJ) within a few months afterwards.